Former Neumora CEO to lead Galapagos spinout

Former Neumora CEO to lead Galapagos spinout

Henry Gosebruch is now chief executive of the spinout, which has roughly $2.5 billion and plans to use dealmaking to build a research pipeline targeting cancer, viruses and the immune system.

Galapagos announces leadership changes amid planned company split - Pharmafile

Galapagos NV has announced key leadership changes as it prepares to separate into two independent entities. Henry Gosebruch has been appointed founding CEO of the newly created subsidiary, currently named SpinCo. The subsidiary, which will operate independently following the split, is funded by Galapagos.  Gosebruch joins SpinCo with extensive experience in business development and mergers […] The post Galapagos announces leadership changes amid…